{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-25-000135","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.488836+00:00","generated_at":"2026-05-17T06:15:14.683290+00:00","sec_items":["1.01","3.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Salarius amends merger deal with Decoy; sets preferred conversion floor at $3.75","bullets":["Fifth Amendment to Merger Agreement sets initial conversion price at $10.50/share for Series A & B Preferred.","Price protection adjusted using spread between $10.50 baseline and any dilutive subsequent financing.","Floor price of $3.75/share set as lowest conversion price in price protection calculations.","Series B Preferred redemption price changed to $10.50 multiplied by 1,000 per share.","All other Merger Agreement terms remain in full force and effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-25-000135","json":"https://secwatch.observer/filing/0001615219-25-000135.json","markdown":"https://secwatch.observer/filing/0001615219-25-000135.md","text":"https://secwatch.observer/filing/0001615219-25-000135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000135/0001615219-25-000135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000135/flks-20250917.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:15:14.683290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"810405ddcc6ae41439f66dac6d33bc3782edd8d9","claim":"Decoy Therapeutics Inc. issued preferred stock.","evidence_excerpt":"On September 17, 2025, the Company entered into a Fifth Amendment to Agreement and Plan of Merger (the “Fifth Amendment”) to modify the conversion terms of the Company’s form of Certificate of Designations of Series A Non-Voting Convertible Preferred Stock (“Series A Preferred Stock”) and Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Stock”, and together with the Series A Preferred Stock, the “Preferred Stock”)","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000135/0001615219-25-000135-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}